<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522662</url>
  </required_header>
  <id_info>
    <org_study_id>Behcet1070806</org_study_id>
    <nct_id>NCT03522662</nct_id>
  </id_info>
  <brief_title>Anti IL-18 (GSK1070806) in Behcet's Disease</brief_title>
  <official_title>An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary outcome measure of the study is to demonstrate the safety and tolerability of&#xD;
      GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical&#xD;
      efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease&#xD;
      important secondary and exploratory outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of all moderate, severe and life threatening adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All adverse events, including mild events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of disease activity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Using a clinical scoring tool, the Behcet's disease current activity form (BDCAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the accumulation of damage</measure>
    <time_frame>24 weeks</time_frame>
    <description>Using a clinical scoring tool, the Vasculitis Damage Index (VDI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of serum free IL-18 and total IL-18 levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Pre and post GSK1070806</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of downstream Th1 cytokines</measure>
    <time_frame>6 weeks</time_frame>
    <description>Including interferon gamma, IP-10, IL-10, IL-2, IL-1β and TNF. Pre and post GSK1070806.</description>
  </other_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Behcet's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1070806</intervention_name>
    <description>Single 10mg/kg infusion on Day 0</description>
    <other_name>anti IL-18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given written informed consent to participate&#xD;
&#xD;
          -  Be aged 18 years and over&#xD;
&#xD;
          -  Have a diagnosis of Behcet's disease (according to the International Study Group (ISG)&#xD;
             diagnostic guidelines or International Criteria for BD (ICBD)).&#xD;
&#xD;
          -  Have active disease, severe enough to necessitate the use of biological therapy at the&#xD;
             time of enrolment (i.e. Subjects have refractory disease as defined by the UK Centres&#xD;
             of Excellence criteria as failure to respond to steroid and/or immunosuppressive&#xD;
             therapy with significant or major organ-threatening disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age under 18 years&#xD;
&#xD;
          2. Allergies to humanized monoclonal antibodies&#xD;
&#xD;
          3. Subjects who have received any of the following agents within 364 days of day 0:&#xD;
&#xD;
               1. Alemtuzumab&#xD;
&#xD;
               2. Rituximab or any other B cell depleting or modulating biological agent&#xD;
&#xD;
          4. Subjects who have received any of the following agents within 180 days of day 0:&#xD;
&#xD;
               1. Cyclophosphamide&#xD;
&#xD;
               2. Anti-thymocyte globulin&#xD;
&#xD;
          5. Subjects who have received any of the following agents within 90 days of Day 0:&#xD;
&#xD;
               1. Intravenous immunoglobulin (IVIG)&#xD;
&#xD;
               2. Plasmapheresis&#xD;
&#xD;
          6. Subjects who have received any of the following agents within 30 days of Day 0:&#xD;
&#xD;
               1. Anti-TNF (e.g. adalimumab, etanercept, infliximab)&#xD;
&#xD;
               2. Anti-IL-6 therapy (e.g. tocilizumab)&#xD;
&#xD;
               3. Interleukin-1 receptor antagonist (e.g. anakinra)&#xD;
&#xD;
               4. Alpha interferon&#xD;
&#xD;
               5. Any live vaccine&#xD;
&#xD;
          7. Subjects who have received any other investigational product within 30 days, 5 half&#xD;
             lives or twice the duration of the biological effect, whichever is longer.&#xD;
&#xD;
          8. Subjects required more than 15mg prednisolone daily in the 4 week run in phase.&#xD;
&#xD;
          9. Positive human immunodeficiency virus (HIV) antibody test&#xD;
&#xD;
         10. Positive serology for Hepatitis B (HB), defined as: (i) HB surface antigen positive&#xD;
             (HBsAg+) OR (ii) HB core antibody positive (HBcAb+)&#xD;
&#xD;
         11. Positive Hepatitis C (HCV) antibody test&#xD;
&#xD;
         12. Evidence of active or latent tuberculosis (TB) as documented by medical history and&#xD;
             examination, chest X-rays (posterior anterior and lateral), and a positive (not&#xD;
             indeterminate) QuantiFERON®-TB Gold test.&#xD;
&#xD;
         13. Evidence of chronic infection requiring long term antimicrobial therapy&#xD;
&#xD;
         14. Serum IgG level &lt; 3g/l&#xD;
&#xD;
         15. Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or&#xD;
             squamous epithelial carcinomas of the skin that have been resected with no evidence of&#xD;
             metastatic disease for 3 years, and carcinoma in situ of the uterine cervix.&#xD;
&#xD;
         16. QTc interval (single or average) &gt; 480msec or in subjects with bundle branch block QTc&#xD;
             &gt; 500msec (these criteria do not apply to subjects with predominantly paced rhythm).&#xD;
&#xD;
         17. Liver function: ALT &gt; 2xULN and bilirubin &gt; 1.5 ULN (isolated bilirubin &gt; 1.5 ULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt; 35%)&#xD;
&#xD;
         18. Compliance: is unlikely to comply with scheduled study visits based on investigator&#xD;
             judgment or has a history of substance abuse, psychiatric disorder or condition that&#xD;
             may compromise communication with the investigator&#xD;
&#xD;
         19. Women who are pregnant or breast feeding&#xD;
&#xD;
         20. Women of child bearing potential who are unwilling or unable to use an acceptable&#xD;
             method to avoid pregnancy for one month before and 12 months after administration of&#xD;
             GSK1070806&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rona M Smith, MD MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rona M Smith, MD MRCP</last_name>
    <phone>00441223217259</phone>
    <email>rona.smith@addenbrookes.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, University of Cambridge NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr. Rona Smith</investigator_full_name>
    <investigator_title>Dr Rona Smith</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

